SCHEMBL6011040

SCHEMBL6011040

O=C(CN1CCCOCC1)N1CCC(/C=C/c2ccc(Cl)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GFER P55789 1/20 0.46
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.41
FKBP1A P62942 1/20 0.40
NAMPT P43490 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2718666 0.96 MAOB (0.50) MAOBNPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL2718661 0.96 MAOB (0.50) MAOBNPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL6012034 0.96 MAOB (0.50) MAOBNPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL10069713 0.89 ALDH1A1 (0.49) MAOBNPC1RAB9ASMN1; SMN2ALOX15
SCHEMBL6011036 0.87 ALOX15 (0.50) MAOBNPC1SMN1; SMN2ALOX15TSHR
SCHEMBL14261815 0.84 MAOB (0.50) MAOBL3MBTL1ALOX15TSHRHSD17B10
SCHEMBL6012010 0.84 TSHR (0.48) MAOBNPC1L3MBTL1SMN1; SMN2ALOX15
SCHEMBL6011051 0.84 ALOX15 (0.48) MAOBNPC1SMN1; SMN2ALOX15TSHR
SCHEMBL6011774 0.84 ALDH1A1 (0.53) MAOBNPC1RAB9ASMN1; SMN2ALOX15
SCHEMBL6011748 0.84 MAOB (0.50) MAOBNPC1ALOX15TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D MAOB 3198/4885NPC1 762/4885RAB9A 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.